KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Long-Term Debt Repayments (2018)

Arbutus Biopharma (ABUS) has disclosed Long-Term Debt Repayments for 1 consecutive years, with $12.0 million as the latest value for Q1 2018.

  • Quarterly Long-Term Debt Repayments changed N/A to $12.0 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $12.0 million through Dec 2018, changed N/A year-over-year, with the annual reading at $12.0 million for FY2018, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $12.0 million in Q1 2018 for Arbutus Biopharma.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $12.0 million in Q1 2018 to a low of $12.0 million in Q1 2018.